These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 30407206)

  • 1. Interleukin-4/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma.
    Wu AY; Sur S; Grant JA; Tripple JW
    Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):30-37. PubMed ID: 30407206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dupilumab for the treatment of asthma.
    Pelaia C; Vatrella A; Gallelli L; Terracciano R; Navalesi P; Maselli R; Pelaia G
    Expert Opin Biol Ther; 2017 Dec; 17(12):1565-1572. PubMed ID: 28990423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological therapies for eosinophilic asthma.
    Patel SS; Casale TB; Cardet JC
    Expert Opin Biol Ther; 2018 Jul; 18(7):747-754. PubMed ID: 29938543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.
    Bagnasco D; Ferrando M; Varricchi G; Passalacqua G; Canonica GW
    Int Arch Allergy Immunol; 2016; 170(2):122-31. PubMed ID: 27637004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgE and eosinophils as therapeutic targets in asthma.
    Patel TR; Sur S
    Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies for the treatment of refractory asthma.
    Hambly N; Nair P
    Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs.
    Parulekar AD; Kao CC; Diamant Z; Hanania NA
    Curr Opin Pulm Med; 2018 Jan; 24(1):50-55. PubMed ID: 29036019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab utility in difficult-to-treat asthma.
    M Walsh G
    Immunotherapy; 2019 Mar; 11(4):261-264. PubMed ID: 30678554
    [No Abstract]   [Full Text] [Related]  

  • 9. Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma.
    Walsh GM
    Expert Rev Respir Med; 2018 Nov; 12(11):957-963. PubMed ID: 30193532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
    Kraft M; Worm M
    Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab for the treatment of asthma.
    Santini G; Mores N; Malerba M; Mondino C; Anzivino R; Macis G; Montuschi P
    Expert Opin Investig Drugs; 2017 Mar; 26(3):357-366. PubMed ID: 28085503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma - an update.
    Walsh GM
    Expert Rev Clin Immunol; 2017 Feb; 13(2):143-149. PubMed ID: 27459348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inflammatory cytokines (IL-4, IL-5 and IL-13)].
    Maeda S; Yanagihara Y
    Nihon Rinsho; 2001 Oct; 59(10):1894-9. PubMed ID: 11676128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single and Synergistic Effects of Type 2 Cytokines on Eosinophils and Asthma Hallmarks.
    Beckert H; Meyer-Martin H; Buhl R; Taube C; Reuter S
    J Immunol; 2020 Feb; 204(3):550-558. PubMed ID: 31862712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab: Basic aspects and applications to allergic diseases.
    Matsunaga K; Katoh N; Fujieda S; Izuhara K; Oishi K
    Allergol Int; 2020 Apr; 69(2):187-196. PubMed ID: 32007360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update.
    Walsh GM
    Expert Opin Biol Ther; 2020 Oct; 20(10):1237-1244. PubMed ID: 32529893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation.
    Nixon J; Newbold P; Mustelin T; Anderson GP; Kolbeck R
    Pharmacol Ther; 2017 Jan; 169():57-77. PubMed ID: 27773786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic and New Therapies in Asthma.
    Tabatabaian F; Ledford DK; Casale TB
    Immunol Allergy Clin North Am; 2017 May; 37(2):329-343. PubMed ID: 28366480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancements in biologic therapy in eosinophilic asthma.
    Patadia R; Casale TB; Fowler J; Patel S; Cardet JC
    Expert Opin Biol Ther; 2024 Apr; 24(4):251-261. PubMed ID: 38619468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commonality of the IL-4/IL-13 pathway in atopic diseases.
    Gandhi NA; Pirozzi G; Graham NMH
    Expert Rev Clin Immunol; 2017 May; 13(5):425-437. PubMed ID: 28277826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.